Diagnosis of oligodendroglioma: Molecular and classical histological assessment in the twenty‐first century

Advances in molecular genetics are currently challenging the traditional morphological categorization of gliomas. Recurrent molecular and cytogenetic aberrations add prognostic and predictive information over and above that provided by standard histomorphological techniques and may influence decisions to re‐operate or observe, to deliver radiation or not, or to administer chemotherapy to glioma patients. The importance of routine hematoxylin and eosin (H–E pathological stains cannot be underestimated, especially in resource‐poor areas and developing countries where there is likely to be a significant economic opportunity cost for molecular diagnosis services. New research tools for image analyses of histological H–E slides, such as the precise measures of cell area, curvature and nuclear roundness, may provide an increased ability to provide an accurate classification for an inherently subjective process of histological assessment. We discuss the current trends, limitations and impact of molecular classification in this mini review.

[1]  J. H. Kim Russell and Rubinstein's Pathology of Tumors of the Nervous System. , 2000 .

[2]  R. McLendon,et al.  Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium , 2008, Cancer Epidemiology Biomarkers & Prevention.

[3]  D. Schiff,et al.  Update on molecular findings, management and outcome in low-grade gliomas , 2010, Nature Reviews Neurology.

[4]  C. Johansen,et al.  Incidence of and survival from oligodendroglioma in Denmark, 1943-2002. , 2009, Neuro-oncology.

[5]  P. Oei,et al.  Retrospective review of prognostic factors, including 1p19q deletion, in low‐grade oligodendrogliomas and a review of recent published works , 2009, Journal of medical imaging and radiation oncology.

[6]  R. McLendon,et al.  Russell and Rubinstein's Pathology of Tumours of the Nervous System, 7th edn , 2007 .

[7]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[8]  Serge Blond,et al.  Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? , 2010, Neuro-oncology.

[9]  C. Mclachlan,et al.  Does cellular heterogeneity influence neuroblastoma cell line proliferation and invasiveness with granulocyte colony-stimulating factor? , 2009, Journal of Pediatric Surgery.

[10]  H. Duffau,et al.  Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? , 2008, Journal of Neuro-Oncology.

[11]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[12]  W. Feiden,et al.  WHO-Klassifikation der ZNS-Tumoren , 2008, Der Pathologe.

[13]  Arie Perry,et al.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.

[14]  K. Hoang-Xuan,et al.  Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression , 2001, Neurology.

[15]  S. Kamel‐Reid,et al.  Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing , 2009, BMC health services research.

[16]  D. Brat,et al.  Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. , 2005, American journal of clinical pathology.

[17]  Nicholas F. Marko,et al.  Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study. , 2010, Genomics.

[18]  Takaaki Kirino,et al.  Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  G. Reifenberger,et al.  Molecular Neuropathology of Gliomas , 2009, International journal of molecular sciences.

[20]  Dorothy S. Russell,et al.  Pathology of Tumours of the Nervous System , 1960 .

[21]  W. Feiden,et al.  [WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas]. , 2008, Der Pathologe.

[22]  E. Melhem,et al.  Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status , 2009, Journal of Neuro-Oncology.

[23]  D. Louis,et al.  Survey of treatment recommendations for anaplastic oligodendroglioma. , 2007, Neuro-oncology.

[24]  R. McLendon,et al.  Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. , 2008, Archives of pathology & laboratory medicine.

[25]  K Skullerud,et al.  Can morphology predict 1p/19q loss in oligodendroglial tumours? , 2008, Histopathology.